8-K: Rigel Pharmaceuticals Reports Record 2024 Revenue and Positive Net Income, Provides Optimistic 2025 Outlook

Rigel Pharmaceuticals announces strong fourth quarter and full-year 2024 financial results, including record net product sales and the first full-year net income, alongside a positive outlook for 2025.

Summary

• Rigel Pharmaceuticals reported total revenue of $57.6 million for the fourth quarter of 2024, including $31.0 million from TAVALISSE, $7.4 million from REZLIDHIA, and $8.1 million from GAVRETO.
• Full-year 2024 total revenue reached $179.3 million, with $104.8 million from TAVALISSE, $23.0 million from REZLIDHIA, and $17.1 million from GAVRETO.
• The company achieved record net product sales of $144.9 million in 2024, a 39% increase compared to 2023.
• Rigel generated a full-year net income of over $17 million and increased cash balances by more than $20 million.
• R289 received Fast Track and Orphan Drug designations from the FDA for MDS treatment.
• Rigel anticipates total revenue of $200 to $210 million in 2025, with positive net income expected.
• A regulatory milestone of $3.0 million will be recognized in Q1 2025 from Kissei due to TAVALISSE approval in Korea.
• Rigel received a $4.0 million upfront payment from Dr. Reddys for REZLIDHIA licensing, with potential for up to $36.0 million in future milestone payments.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record revenues, first-time profitability, and promising clinical developments, indicating strong financial health and growth potential.

Positives

• Record net product sales of $144.9 million in 2024, a 39% increase compared to 2023.
• First full-year net income of over $17 million.
• Cash balances increased by more than $20 million during 2024.
• TAVALISSE net product sales grew 21% in Q4 2024 compared to the same period in 2023.
• REZLIDHIA net product sales grew 92% in Q4 2024 compared to the same period in 2023.
• R289 received Fast Track and Orphan Drug designations from the FDA.
• Positive net income is anticipated for the full year 2025.
• TAVALISSE was approved in Korea and Mexico through partnerships.
• Rigel entered an exclusive license agreement with Dr. Reddys Laboratories Ltd. for REZLIDHIA.

Risks

• The forward-looking statements are subject to risks and uncertainties, including those associated with the commercialization and marketing of fostamatinib, olutasidenib and pralsetinib.
• There are risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding fostamatinib, pralsetinib or olutasidenib.
• Clinical trials may not be predictive of real-world results or of results in subsequent clinical trials.
• Fostamatinib, pralsetinib or olutasidenib may have unintended side effects, adverse reactions or incidents of misuses.
• Market competition could impact future performance.

Future Outlook

Rigel anticipates 2025 total revenue of approximately $200 to $210 million, including net product sales of approximately $185 to $192 million and contract revenues from collaborations of approximately $15 to $18 million; the company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.

Management Comments

• 2024 was a year of significant accomplishments for Rigel.
• We continued to focus on commercial expansion and execution, achieving record net product sales of $144.9 million, an increase of 39% compared to 2023.
• Coupled with Rigels commitment to financial discipline, for the first time we generated full-year net income of more than $17 million and increased our cash balances by more than $20 million.
• These outstanding commercial and financial results provide us the resources to advance our promising internal development programs in 2025, including our ongoing Phase 1b clinical study of R289 for the treatment of lower-risk MDS and the initiation of a Phase 2 clinical study of olutasidenib for the treatment of recurrent glioma.
• Raul Rodriguez, Rigels president and CEO, made these statements.

Industry Context

Rigel's focus on hematologic disorders and cancer aligns with the growing demand for novel therapies in these areas, as evidenced by the market performance of TAVALISSE, REZLIDHIA, and GAVRETO; the FDA's Fast Track and Orphan Drug designations for R289 highlight the unmet need for effective treatments in lower-risk MDS.

Comparison to Industry Standards

• Comparing Rigel's performance to similar biotechnology companies focused on hematology and oncology, companies like Kura Oncology and Geron Corporation are also developing therapies for MDS and AML.
• Rigel's revenue growth and profitability metrics can be benchmarked against these companies to assess its relative success.
• For example, Kura Oncology is focused on developing next generation therapeutics for the treatment of cancer, including tipifarnib for HRAS mutant HNSCC.
• Geron Corporation is focused on developing therapeutics for hematologic malignancies, including imetelstat for lower risk MDS.
• Rigel's strategic collaborations, such as the licensing agreement with Dr. Reddys, are common in the industry to expand market reach and share development costs.

Stakeholder Impact

• Shareholders will benefit from the company's increased profitability and positive outlook.
• Employees may see increased job security and potential for growth within the company.
• Patients will have access to potentially life-improving therapies for hematologic disorders and cancer.
• Partners and collaborators will benefit from the company's continued success and expansion.
• Creditors will have increased confidence in the company's ability to meet its financial obligations.

Next Steps

• Advance the Phase 1b clinical study of R289 for lower-risk MDS.
• Initiate a Phase 2 clinical study of olutasidenib for recurrent glioma.
• Continue commercial expansion and execution for TAVALISSE, REZLIDHIA, and GAVRETO.
• Recognize a $3.0 million regulatory milestone from Kissei in Q1 2025.
• Advance the four studies outlined in the multi-year strategic development alliance with The University of Texas MD Anderson Cancer Center.

Key Dates

Keywords

Rigel Pharmaceuticals, Financial Results, TAVALISSE, REZLIDHIA, GAVRETO, R289, Net Income, Revenue, MDS, AML, ITP